2.48
+0.3(+13.76%)
Currency In USD
| Previous Close | 2.18 |
| Open | 2.2 |
| Day High | 2.5 |
| Day Low | 2.25 |
| 52-Week High | 13.5 |
| 52-Week Low | 0.99 |
| Volume | 2.3M |
| Average Volume | 1.38M |
| Market Cap | 125.84M |
| PE | -0.98 |
| EPS | -2.54 |
| Moving Average 50 Days | 1.45 |
| Moving Average 200 Days | 2.82 |
| Change | 0.3 |
If you invested $1000 in Cabaletta Bio, Inc. (CABA) since IPO date, it would be worth $248 as of June 07, 2025 at a share price of $2.48. Whereas If you bought $1000 worth of Cabaletta Bio, Inc. (CABA) shares 5 years ago, it would be worth $283.43 as of June 07, 2025 at a share price of $2.48.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cabaletta Bio to Participate in the Jefferies Global Healthcare Conference
GlobeNewswire Inc.
May 29, 2025 12:00 PM GMT
PHILADELPHIA, May 29, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimm
Cabaletta Bio Announces 2027 Rese-cel BLA Submission Anticipated in Myositis Following Recent FDA Alignment on Registrational Cohorts
GlobeNewswire Inc.
May 15, 2025 11:00 AM GMT
– Two subtype specific cohorts with ~15 patients each added to the ongoing RESET-Myositis™ trial – – RMAT designation granted for rese-cel in myositis, which is a disabling, multi-system autoimmune disease affecting approximately 80,000 U.S. p
Cabaletta Bio to Participate in the TD Cowen 45th Annual Health Care Conference
GlobeNewswire Inc.
Feb 26, 2025 1:00 PM GMT
PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoim